Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Şebnem YÜCEL"'
Autor:
Havva Nur Atalay, Şebnem Yücel
Publikováno v:
Archives of Public Health, Vol 82, Iss 1, Pp 1-13 (2024)
Abstract Background Personal health data is crucial for effective medical care, personalized treatment, and health monitoring. It enables accurate diagnosis, efficient treatment plans, and informed healthcare decisions. Personal health data should be
Externí odkaz:
https://doaj.org/article/44742ce7f06c4b34975b4c63431fd08b
Publikováno v:
Ankara Medical Journal, Vol 19, Iss 4, Pp 729-735 (2019)
Giriş: İnflamasyon kanser gelişimini kolaylaştırmanın yanı sıra birçok kanser tipinde kötü prognozla da ilişkilidir. Albümin ve globülin inflamasyonu yansıtan belirteçlerden ikisidir. Albüminin özellikle inflamasyon dışı birçok
Externí odkaz:
https://doaj.org/article/95bb7a8461dd40799340fafe56c7ad2c
Autor:
Şebnem Yücel
Publikováno v:
International Journal of Islamic Architecture. 12:213-226
Publikováno v:
Journal of Oncological Sciences. 9:50-52
Autor:
Şebnem Yücel
Publikováno v:
International Journal of Islamic Architecture. 11:171-183
Autor:
Mustafa Gürbüz, Saadettin Kiliçkap, Ahmet Bilici, Nuri Karadurmuş, Ahmet Sezer, Mehmet Ali Nahit Şendur, Semra Paydaş, Mehmet Artaç, Perran Fulden Yumuk, Pinar Gürsoy, Mükremin Uysal, Hasan Şenol Coşkun, Ali Murat Tatli, Fatih Selçukbiricik, Umut Dişel, Elif Berna Köksoy, Deniz Can Güven, Muzaffer Uğrakli, Erman Akkuş, Şebnem Yücel, Cihan Erol, Serdar Karakaya, Teoman Şakalar, Nijat Khanmammadov, Nail Paksoy, Ahmet Demirkazik
Publikováno v:
Medicine. 101(50)
Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterat
Autor:
ŞEBNEM YÜCEL
Publikováno v:
Book of abstracts.
Autor:
Sadettin Kilickap, Mutlu Hizal, Ahmet Gulmez, Okan Avci, Burak Yasin Aktas, Havva Yesil Cinkir, Emir Celik, Mustafa Gürbüz, Berna Oksuzoglu, Ali Murat Tatli, Gulhan Ipek Deniz, Cihan Erol, Erdem Sen, Fulden Yumuk, A İlhan, Şebnem Yücel, Semra Paydas, Ozkan Alan, Engin Kut, Fatih Karatas, Atakan Demir, Murat Ayhan, Bulent Yalcin, Halil Taskaynatan, Tugba Basoglu, Serkan Menevse, Deniz Tataroğlu Özyükseler, Nadiye Akdeniz, Sinan Koca, Mustafa Karaagac, Burak Bilgin, Didem Sener Dede, Mehmet Ali Nahit Sendur, Muhammed Bulent Akinci, Izzet Dogan, Ahmet Demirkazik, Teoman Sakalar
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:2145-2152
The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that invest
Autor:
Burak Bilgin, Şebnem Yücel
Publikováno v:
Acta Oncologica Turcica. 54:17-22